The Best Time to Start Hormone Therapy for Your Heart — Does It Matter?
Part 4 of 4 in our series: Menopause Hormone Therapy and Your Heart Just joining us? Start with Part 1, Part 2, and Part 3.
By now we know that the relationship between hormone therapy and heart health isn't a simple yes or no. We know that timing matters, that the women in the big studies weren't always representative of the women asking the questions, and that earlier research had some significant blind spots.
So researchers decided to go back and test the timing hypothesis directly — with younger, recently menopausal women. The results were... complicated. In the best possible way.
Two Studies That Tried to Find the Answer
The KEEPS Trial
Researchers enrolled 727 healthy women who were within just 3 years of menopause — the kind of women who show up in a doctor's office asking about hot flashes and sleep problems. They had normal cardiac screening at baseline and were given transdermal estradiol with micronized progesterone. The question: would starting hormones early show clear cardiovascular benefit?
The honest answer? Not in the ways hoped for. After the study period — and even in a 14-year follow-up — there was no significant improvement in key markers of arterial disease and no clear cardiovascular or metabolic advantage over placebo. It was a sobering result for those expecting a clean win.
The ELITE Trial
This one took a smarter angle. Instead of just studying early starters, the ELITE trial split 643 women into two groups: those within 6 years of menopause and those 10 or more years past menopause. Both groups received oral estradiol with vaginal micronized progesterone. The comparison between groups was the real story.
And here, the timing hypothesis found its strongest support yet. Women who started hormones early showed a 44% slower progression of subclinical atherosclerosis — the quiet early buildup of plaque that precedes visible heart disease — compared to women who started late, who showed no benefit at all. That's a meaningful difference.
However — and this is important — coronary artery calcium scores and direct measurements of plaque and narrowing didn't differ significantly between groups.
What the Bigger Picture Shows
Beyond these individual trials, multiple recent meta-analyses — studies that pool and analyze data across many trials at once — are now consistently showing that women who start hormone therapy within 10 years of menopause or before age 60 have a significantly lower risk of coronary heart disease and lower overall mortality compared to those who start later or not at all.
The evidence is building. But it remains layered, and no single study has delivered a clean knockout punch.
So What Does This All Mean for You?
Let's be clear about one important point upfront: hormone therapy is not prescribed for the purpose of preventing heart disease. That's not what it's indicated for, and the evidence doesn't currently support using it that way.
But here's what the science does tell us — and what every woman approaching or going through menopause deserves to know:
Timing is everything. Starting hormone therapy within 10 years of menopause is associated with potential cardiovascular benefit — particularly with estrogen alone — and at minimum a neutral to protective effect with estrogen-progestin combinations. Starting more than 20 years after menopause can increase cardiovascular risk. The window matters.
Your symptoms are telling you something. Severe hot flashes aren't just uncomfortable — they are independently associated with greater cardiovascular risk. Managing your symptoms isn't vanity. It's health.
Hormone therapy should not be started to prevent heart disease — either for the first time (primary prevention) or after a cardiac event (secondary prevention). This is firm guidance, and it hasn't changed.
But if you're starting hormone therapy for quality of life — for sleep, for hot flashes, for mood, for bone health — starting early may bring heart benefits along for the ride. And that's not nothing.
The Bottom Line
This four-part journey has taken us from the hopeful headlines of the 1980s, through the panic of 2002, into the nuanced and still-evolving science of today. Here's the distilled wisdom:
Hormone therapy can carry real risk in women with existing heart disease
The WHI told us how women who are well past menopause respond to hormone therapy
Timing matters more than almost anything else — earlier is generally safer and potentially beneficial for the heart
Hot flashes are more than a nuisance — they're a cardiovascular signal
Hormone therapy is not a heart disease prevention strategy — but in the right woman, at the right time, it may be a welcome bonus
The conversation between you and your doctor should be exactly that — a conversation. About your age, how long it's been since your last period, your symptoms, your risk factors, and your goals. The science is more nuanced than any headline ever captured.
Before you close this tab, there's one more thing worth knowing. The WHI — the study that shaped two decades of fear around hormone therapy — wasn't testing the hormones most women are prescribed today. It used CEE and MPA, older formulations that have largely been replaced by estradiol and micronized progesterone in modern menopause care. On top of that, we now have transdermal estrogen — patches and gels that bypass the liver entirely and don't raise clotting factors the way oral estrogen does. That's not a small detail. It could change everything. The large-scale trials on these modern formulations haven't been done yet — but when they are, the results may look very different from what we saw in 2002. The science isn't finished. And for women navigating menopause today, that's reason for cautious optimism.
And now you have the full story.
Missed any part of this series? Part 1: "Hormones and Your Heart: Why Doctors Keep Changing Their Minds" Part 2: "The Hormone Scare of 2002 — Were We Right to Panic about our hearts?" Part 3: "The Fine Print Nobody Read in the Big Hormone Study"
